Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 20 years old and active cancer and newly-diagnosed, symptomatic or incidental proximal lower extremity DVT, PE or both~* will have a life expectancy \> 3 months~* will be treated with anticoagulation therapy for at least 3 months.~Exclusion Criteria:~* (1) Isolated asymptomatic distal DVT~* (2) Intra-abdominal venous thrombosis or vascular access-induced thrombosis~* (3) Hemodynamically unstable PE, indicating systolic blood pressure \<90 mmHg~* (4)Eastern Cooperative Oncology Group (ECOG) performance status score of 3 or 4~* (5) History of total gastrectomy~* (6) Overt brain metastasis. Patients who have controlled brain metastasis without need of glucocorticoid are eligible~* (7) History of recent major or clinically relevant bleeding within the previous 4 weeks~* (8) Conditions associated with a high risk of serious bleeding (active peptic ulcer or recent neurosurgery)~* (9) Other serious illness or medical conditions (illnesses requiring chronic anticoagulation therapy, unstable cardiac disease despite treatment, myocardial infarction within 3 months prior to study entry, significant neurologic or psychiatric diseases including dementia or seizure, active uncontrolled infection, other serious medical conditions)~* (10)Inadequate renal function; creatinine clearance \< 30 ml/min~* (11) Inadequate hepatic function: alanine aminotransferase \> 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase \> 5 times the ULN or total bilirubin \>2 times the ULN (if liver metastasis, total bilirubin \>3 times the ULN)~* (12) Baseline platelet count \< 75,000 per cubic millimeter or Hb \< 8g/dL~* (13) Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the bleeding risk~* (14) Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period, who are using a prohibited contraceptive method, or who are pregnant or breastfeeding~* (15) Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin, phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic ketoconazole) treatments~* (16) Patients with inferior vena cava filter placement or underwent catheter-directed thrombolysis or stent placement for the treatment of index VTE

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral rivaroxaban in cancer-associated VTE (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).